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This is the ninth consecutive year I have taught the core course in
epidemiology in the Executive MPH (EMPH) Program at Columbia
University and, not coincidentally, the ninth year I chose as my
textbook Epidemiology by Leon Gordis. No other epidemiology
textbook I know of comes close to meeting the unusual demands of
this Program.
The EMPH Program, offered by the Dept. of Health Policy and
Management, provides mid-career professionals with skills relevant
to management of both public and private health care and research
institutions. A selected cohort of students meets for one 4-day
weekend per month for two years, taking the same curriculum as the
regular MPH students, but with most classes restricted to EMPH
enrollees. The course's 42 contact hours are spread over 12 classroom
sessions in six months. The students are a mix of physicians, lawyers,
hospital administrators, Health Department employees, nurses, and
clinical managers. A successful textbook must speak a language
accessible to all, cover essential concepts in a way that doesn't put
clinicians to sleep, overwhelm non-physicians with medical jargon, or
use advanced mathematical methods outside the experience of either
group. It must present some of the rich history of the field, not shy
away from controversies, yet not give the impression that epidemi-
ology is hopelessly inadequate to meet the needs of public policy.
Gordis meets these requirements and more.
The new 4th edition is 36 pages longer than the 3rd, due more to
layout changes than to new text. The most obvious feature distinguish-
ing the 4th edition from its predecessor is that the book has been tarted
up with color versions of previously black and white drawings. The
typeface for most tables was adjusted to match the text. These
enhancements make the book's overall look and feel inviting to the
student. This is important because the book contains an immense
amount ofmaterial. Practically no important topic is omitted— there are
chapters on basic measures, major observational study designs (cohort
and case-control studies), clinical trials, causal inference, bias and
confounding, screening, genetics, and surveillance. The 3rd edition had
introduced some badly needed material on outcomes and service
evaluation, which guest lecturers formerly covered, and this is retained.
The many tables and charts that show disease occurrence statistics
over time were updated to the most recently available year. The
excellent section on outbreak investigation, with its classic “was-it-
the-egg-salad?” example, is still there and some administratively
useful procedures have been added to Tables 2–4 “Steps in
investigating an acute outbreak.”
I have always likedGordis's treatmentof life tables andKaplan–Meier
methods (Chapter 6). Some instructors find it long-winded and overly
detailed, but my philosophy of life tables is that every epidemiologist
should work an example of both methods by hand at least once to see
how the logic works. Gordis presents this superbly. Some useful new
material (1 paragraph and four small figures, pp. 126–7) has been added
to better explain relative survival rates.
It is remarkable how well Gordis captures the quantitative aspects
of cohort studies, case-control studies, and randomized clinical trials
using high school level math, well-chosen examples, and excellent
illustrations. Chapter 10 on case-control studies has new material on
nested studies, a short section on case-cohort studies, and one on case-
crossover designs (pp. 194–5). In explaining frequency matching in
case-control studies, Gordis states that cases must generally be
selected before the controls in order to determine the joint frequency
of matching variables. However, investigators who work in hospitals
with stable admission practices and computerized admission files can
often determine quotas for controls before interviewing begins,
permitting concurrent interviewing of cases and controls (Stellman
et al., 2003).
Health policy students especially appreciate learning how
epidemiological controversies have played out in the public arena.
One apt example that Gordis covers at some length is the storm that
arose when three separate animal feeding studies found excess
bladder tumors in rats fed high doses of saccharin. As a matter of
public policy, the animal findings should have obligated the FDA to
ban saccharin as a food additive, under the Delaney Amendment to
the Food, Drug, and Cosmetic Act, which forbade use of demon-
strably carcinogenic compounds as food additives (Epstein, 1979).
However, shortly afterwards an NCI case-control study of saccharin
and bladder cancer reported no association (Hoover and Strasser,
1980). Other studies followed, nearly all of which were also null
(Committee on the Evaluation of Cyclamate for Carcinogenicity,
1985), including one of my own (Wynder and Stellman, 1980).
Referring to the NCI study, Gordis states “… the investigators in this
study did not confirm the findings that had been reported in animal
studies, which had caused considerable controversy and had major
policy implications for government regulation.” Gordis's account
stops there, but there is more to the story. That mandatory ban, duly
proposed by FDA Commissioner Donald Kennedy, didn't happen.
Intense lobbying, helped along by the soft drink industry's Calorie
Control Council, resulted in a saccharin-specific Congressional
exception to the Delaney Amendment. The exception was renewed
regularly until the Delaney Amendment itself was finally repealed in
1996.
Gordis nicely tackles interaction, which he illustrates (Fig. 15-5)
with a French study of alcohol and tobacco use (Tuyns et al., 1977).
These well-known IARC data have been reproduced and circulated in
epidemiology classes at Columbia for decades. However, Tuyns's
subtitle is translated literally as “risks are multiplying,” whereas from
the context of the article, a better translation might be “multiplicative
risks.”
In Chapter 17 on health services evaluation there is useful
rewriting. Newmaterial has been inserted in the section on Outcomes
Research, with a presentation of data from the Birkmeyer et al. (2003)
study of operative mortality in Medicare patients.
Chapter 19 on policy has two important additions. (1) A section on
the impact of hormone replacement therapy findings on policy (pp.
337–9) uses theWomen's Health Initiative as an example. (2) There is
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a new section on sources and impact of uncertainty that could be a
take-off point for an entire lecture if not another course.
In contrast to the strengths noted above, there is very little
material on molecular epidemiology and no chapter on genetic
epidemiology per se. A chapter titled “Identifying the roles of genetic
and environmental factors in disease causation” introduces elemen-
tary concepts of genetics and reviews some of the classic migrant
studies, but its hurried treatment of central concepts such as genetic
markers, polymorphisms, and microarray technology, and study
designs like family and twin studies, as well as the somewhat
haphazard sequence of topics make it more difficult to teach from
than other chapters. Furthermore, the field is changing rapidly and
many examples are in danger of becoming out of date.
Nearly every chapter concludes with a summary, a set of
references, and half a dozen or so well thought out multiple-choice
exercises that are ideal for self-study. However, the answer keymerely
indicates the correct choice,which is not very helpful. Therefore, I have
developed an annotated set of worked-out solutions to all of the
problems that I post on the course website after each chapter is
covered.
Selecting a beginning epidemiology textbook can be a daunting
task. I was already aware that earlier editions of Gordis had been used
successfully in the version of this Core course that is taught to all MPH
students at Columbia. It is not as quantitative or methodologically
oriented as Szklo and Nieto (2007) or as chronic disease focused as
Aschengrau and Seage (2003), both of which have also been used
here. Nevertheless, it fully covers the fundamental issues that Bhopal
(1997) in his review of 25 textbooks considers essential to a modern
text.
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